Sagimet Biosciences Inc (SGMT) Stock AnalysisSGMTStock AnalysisSagimet Biosciences Inc

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sagimet Biosciences Inc is a good buy right now due to its current price of $10.55, which is significantly below the analyst price target of $56 from Canaccord. The company has a strong cash position of $257.6 million, sufficient to fund operations through 2028, which supports its ongoing clinical trials. However, the main risk is the negative earnings per share (EPS) of -0.26 reported for Q2 2026, indicating ongoing financial losses.